Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity Inc. has demonstrated significant stock appreciation of approximately 608% year-to-date, outperforming major indices, which underscores strong investor interest and confidence in the company's potential. The positive outlook is bolstered by promising clinical trial results for gedatolisib, with improved safety profiles reported in the ongoing Phase 3 VIKTORIA-1 trial and an increased probability of launch raised to 90%. Additionally, with raised sales estimates reflecting expedited regulatory pathways and market potential, the financial projections for gedatolisib have also been adjusted upward, indicating an expansive opportunity for revenue generation in the oncology market.

Bears say

Celcuity Inc. is currently facing a negative outlook primarily due to concerns about its financial position, highlighted by a significant estimated R&D spend of $35 million, which, despite being down 13% sequentially, raises questions about the company's cash management in a clinical stage. The FDA's acceptance of the NDA application for gedatolisib offers potential upside; however, any delays in the anticipated approval timeline could adversely impact market sentiment and stock performance. Furthermore, potential competition from larger pharmaceutical companies and the risk of lower-than-expected pricing power due to higher discounts from payors contribute to the cautious sentiment surrounding Celcuity's valuation at $4.3 billion, leading to a recommendation for investors to remain cautious.

Celcuity (CELC) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Buy based on their latest research and market trends.

According to 9 analysts, Celcuity (CELC) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $108.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $108.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.